

1. A method for increasing GC-C Receptor activity, the method comprising administering a composition comprising a chymotrypsin inhibitor.
- 5 2. A method for increasing cGMP levels, the method comprising administering a composition comprising a chymotrypsin inhibitor.
3. A method for treating a disorder ameliorated by increasing cGMP levels, the method comprising administering a composition comprising a chymotrypsin inhibitor.
- 10 4. A method for increasing intestinal motility, the method comprising administering a composition comprising a chymotrypsin inhibitor.
5. A method for treating a patient suffering from or at risk for congestive heart failure, the method comprising administering a composition comprising a chymotrypsin inhibitor.
- 15 6. A method for treating a patient suffering from or at risk for benign prostatic hyperplasia, the method comprising administering a composition comprising a chymotrypsin inhibitor.
- 20 7. A method for treating a patient suffering from or at risk for a gastrointestinal disorder, the method comprising administering a composition comprising a chymotrypsin inhibitor.
8. The method of claim 7 wherein the gastrointestinal disorder is selected from the group consisting of: constipation, a gastrointestinal motility disorder, irritable bowel syndrome, a functional gastrointestinal disorder, gastroesophageal reflux disease, functional heartburn, dyspepsia, functional dyspepsia, nonulcer dyspepsia, gastroparesis, chronic intestinal pseudo-obstruction, and colonic pseudo-obstruction.
- 25 9. A method for treating obesity, the method comprising administering a composition comprising a chymotrypsin inhibitor.
- 30

10. A method for decreasing gastrointestinal pain or visceral pain in a patient, the method comprising administering to the patient a composition comprising a chymotrypsin inhibitor and a pharmaceutically acceptable carrier.

5

11. A method for treating a gastrointestinal disorder, the method comprising:
(a) diagnosing a patient as suffering from a gastrointestinal disorder; and
(b) administering a composition comprising a chymotrypsin inhibitor.

10 12. The method of any of claims 1-11 further comprising administering guanylin or a biologically active variant or fragment thereof.

13. A pharmaceutical composition comprising a chymotrypsin inhibitor and a pharmaceutically acceptable carrier.

15

14. The composition of claim 10 further comprising guanylin or a biologically active variant or fragment thereof.

15. The composition of claim 14 further comprising a GC-C Receptor agonist.

20

16. The method of any of claims 1-11 further comprising administering a GC-C Receptor agonist.

17. The composition of claim 10 further comprising a GC-C Receptor agonist.

25